Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | NAMPT | P43490 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28309713 | 0.88 | CA2 (0.71) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL12330697 | 0.87 | CA2 (0.62) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL6569317 | 0.87 | LMNA (0.72) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL5257811 | 0.87 | LMNA (0.72) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL24975530 | 0.86 | HPGDS (0.64) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL29801099 | 0.86 | HPGDS (0.64) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL1161997 | 0.86 | NAMPT (0.75) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL1568226 | 0.86 | ALDH1A1 (0.72) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL5783915 | 0.85 | HTT (0.71) | CA2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL2972947 | 0.85 | ALDH1A1 (0.71) | CA2ALDH1A1LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | claimed |
| WO-2017144393-A1 | 2-SUBSTITUTED 5-(PHENYL)-1,2-DIHYDRO-3H-3-BENZAZEPINE-3-CARBOXAMIDE DERIVATIVES AS BRD4 INHIBITORS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-31 | — | — | WO | disclosed |
| US-9012419-B2 | Methods and compositions related to eosinophil regulation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012419-B2 | Methods and compositions related to eosinophil regulation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012419-B2 | Methods and compositions related to eosinophil regulation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-21 | — | — | US | disclosed |
| EP-1928879-B1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2343303-A1 | PI3-kinase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| WO-2007136707-A2 | METHODS AND COMPOSITIONS RELATED TO EOSINOPHIL REGULATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136707-A2 | METHODS AND COMPOSITIONS RELATED TO EOSINOPHIL REGULATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | MAP3K2, MAP3K3, MAP4K2 | CA2 2509/4885ALDH1A1 3349/4885LMNA 4763/4885 |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | COL2A1, MMP1, COL1A1 | CA2 3974/4885ALDH1A1 1145/4885LMNA 906/4885 |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | CA2 2127/4885ALDH1A1 4291/4885LMNA 4523/4885 |
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | EPX, CCL11, ELANE | CA2 2811/4885ALDH1A1 2022/4885LMNA 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.